| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
ICLR
Icon
|
May 29, 2026 | HOLD |
Strong Buy
+23.8% avg upside
25 analysts
|
$140.00
4.01% Downside
|
+8.6% |
|
TECH
Bio-Techne
|
May 28, 2026 | BUY |
Strong Buy
+38.3% avg upside
21 analysts
|
$70.00
20.73% Upside
|
+10.2% |
|
NTRA
Natera
|
May 28, 2026 | BUY |
Strong Buy
+7.4% avg upside
26 analysts
|
$300.00
29.72% Upside
|
+5.8% |
|
SHC
Sotera Health
|
May 28, 2026 | BUY |
Strong Buy
+29.6% avg upside
13 analysts
|
$23.00
45.31% Upside
|
+0.2% |
|
DHR
Danaher
|
May 27, 2026 | BUY |
Strong Buy
+21.9% avg upside
45 analysts
|
$230.00
29.90% Upside
|
+2.7% |
|
FTRE
Fortrea Holdings Inc.
|
May 26, 2026 | BUY |
Buy
-3.5% avg upside
11 analysts
|
— | +1.5% |
|
MTD
Mettler-Toledo
|
May 08, 2026 | BUY |
Buy
+2.7% avg upside
18 analysts
|
$1550.00
35.40% Upside
|
+2.7% |
|
CAI
Caris Life Sciences, Inc.
|
May 08, 2026 | BUY |
Strong Buy
+54.5% avg upside
20 analysts
|
$28.00
51.50% Upside
|
+2.1% |
|
BRKR
Bruker
|
May 07, 2026 | HOLD |
Buy
-7.0% avg upside
22 analysts
|
$44.00
23.14% Downside
|
+25.1% |
|
MDLN
Medline
|
May 06, 2026 | BUY |
Strong Buy
+42.9% avg upside
26 analysts
|
$55.00
53.03% Upside
|
-14.4% |
|
QDEL
QuidelOrtho
|
May 06, 2026 | HOLD |
Buy
+183.5% avg upside
13 analysts
|
$13.00
4.81% Downside
|
+19.8% |
|
ILMN
Illumina
|
May 04, 2026 | SELL |
Buy
-10.1% avg upside
30 analysts
|
$95.00
41.37% Downside
|
-14.1% |
|
AVTR
Avantor
|
Apr 30, 2026 | HOLD |
Buy
+49.6% avg upside
26 analysts
|
$9.00
6.02% Downside
|
+16.8% |
|
QGEN
Qiagen
|
Apr 29, 2026 | HOLD |
Buy
+14.1% avg upside
23 analysts
|
$38.00
2.76% Upside
|
-2.5% |
|
WST
West Pharmaceutical Services
|
Apr 24, 2026 | BUY |
Strong Buy
+6.5% avg upside
17 analysts
|
$400.00
22.02% Upside
|
+7.7% |
|
TXG
10x Genomics
|
Apr 07, 2026 | HOLD |
Buy
-27.9% avg upside
18 analysts
|
$24.00
30.85% Downside
|
+45.5% |
|
BIO
Bio-Rad Laboratories
|
Apr 07, 2026 | HOLD |
Buy
+23.7% avg upside
8 analysts
|
$300.00
6.19% Upside
|
+2.4% |
|
WAT
Waters
|
Apr 07, 2026 | BUY |
Strong Buy
+3.6% avg upside
30 analysts
|
$425.00
19.55% Upside
|
+16.1% |
|
IQV
IQVIA Holdings
|
Apr 07, 2026 | HOLD |
Strong Buy
+34.5% avg upside
38 analysts
|
$200.00
19.19% Upside
|
+4.5% |
|
GH
Guardant Health
|
Apr 07, 2026 | BUY |
Strong Buy
-5.9% avg upside
30 analysts
|
$150.00
13.89% Upside
|
+38.4% |
|
STVN
Stevanato Group
|
Apr 07, 2026 | BUY |
Strong Buy
+53.7% avg upside
13 analysts
|
$26.00
48.19% Upside
|
+25.5% |
|
TMO
Thermo Fisher
|
Apr 06, 2026 | BUY |
Strong Buy
+26.8% avg upside
38 analysts
|
$685.00
47.46% Upside
|
-5.3% |
|
A
Agilent
|
Mar 11, 2026 | BUY |
Strong Buy
+3.8% avg upside
32 analysts
|
$185.00
45.63% Upside
|
+8.0% |
|
DGX
Quest Diagnostics
|
Feb 11, 2026 | HOLD |
Buy
-12.4% avg upside
33 analysts
|
$215.00
10.21% Upside
|
-5.1% |
|
CRL
Charles River Labs
|
Jan 15, 2026 | BUY |
Strong Buy
+11.9% avg upside
34 analysts
|
$265.00
43.25% Upside
|
-18.4% |
|
LH
Labcorp Holdings
|
Jan 02, 2026 | BUY |
Strong Buy
+1.8% avg upside
36 analysts
|
$325.00
27.00% Upside
|
+2.2% |
|
RVTY
Revvity
|
May 22, 2025 | BUY |
Buy
+5.2% avg upside
23 analysts
|
$135.00
34.91% Upside
|
+7.5% |
|
OSUR
Orasure Technologies
|
Feb 26, 2025 | BUY |
Buy
+100.0% avg upside
11 analysts
|
$6.00
41.23% Upside
|
-8.9% |
|
SERA
Sera Prognostics
|
Mar 23, 2023 | HOLD |
Strong Buy
+325.6% avg upside
7 analysts
|
$4.25
142.77% Upside
|
+163.8% |
|
BEAM
Beam Therapeutics
|
Mar 01, 2023 | BUY |
Strong Buy
+50.8% avg upside
25 analysts
|
$62.00
81.69% Upside
|
+3.5% |
|
PSNL
Personalis
|
Feb 24, 2023 | BUY |
Strong Buy
+12.8% avg upside
11 analysts
|
$6.00
43.14% Downside
|
+24.6% |
|
ADPT
Adaptive Biotechnologies
|
Aug 14, 2019 | HOLD |
Strong Buy
+19.9% avg upside
14 analysts
|
$36.00
105.38% Upside
|
-9.6% |
|
TTOO
T2 Biosystems
|
Nov 30, 2018 | HOLD |
Buy
+1421150.0% avg upside
10 analysts
|
$4.50
899899.96% Upside
|
· |
|
MYGN
Myriad Genetics
|
Nov 30, 2018 | HOLD |
Hold
+313.3% avg upside
24 analysts
|
$32.00
604.87% Upside
|
-20.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.